Amyloid-beta Burden Predicts Prospective Decline in Body Mass Index in Clinically Normal Adults

Overview

Journal Neurobiol Aging

Publisher Elsevier

Specialties Geriatrics
Neurology
Physiology

Date 2020 Apr 7

PMID 32249013

Citations 15

Authors

Jennifer S Rabin

Zahra Shirzadi

Walter Swardfager

Bradley J MacIntosh

Aaron Schultz

Hyun-Sik Yang

Rachel F Buckley

Jennifer R Gatchel

Dylan Kirn

Jeremy J Pruzin

Trey Hedden

Nir Lipsman

Dorene M Rentz

Sandra E Black

Keith A Johnson

Reisa A Sperling

Jasmeer P Chhatwal

Affiliations

Soon will be listed here.

Abstract

In the present study, we tested the hypothesis that higher amyloid-beta (Aβ) burden at baseline is associated with greater longitudinal decline in body mass index (BMI) in clinically normal adults. Participants from the Harvard Aging Brain Study (n = 312) and the Alzheimer's Disease Neuroimaging Initiative (n = 336) underwent Aβ positron emission tomography at baseline. BMI was assessed longitudinally over a median of >4 years. Linear mixed models showed that higher baseline Aβ burden was significantly associated with greater decline in BMI in both the Harvard Aging Brain Study (t = -1.93; p = 0.05) and Alzheimer's Disease Neuroimaging Initiative cohorts (t = -2.54; p = 0.01), after adjusting for covariates, including cognitive performance and depressive symptoms. In addition, the association of Aβ burden with longitudinal decline in BMI persisted in both cohorts after excluding participants with diabetes/endocrine disturbances and participants classified as underweight or obese (BMI <18.5 or >30). These findings suggest that decline in BMI in clinically normal adults may be an early manifestation related to cerebral amyloidosis that precedes objective cognitive impairment. Therefore, unintentional BMI decline in otherwise healthy individuals might alert clinicians to increased risk of Alzheimer's disease.

Citing Articles

The Association Between Neuropathological Lesions and Body Mass Index Is Independent of Cognitive Abilities.

Ururahy R, do Val M, Ciciliati A, Leite R, Paes V, Rodrigues R J Alzheimers Dis. 2024; 101(3):773-785.

PMID: 39213060 PMC: 11905978. DOI: 10.3233/JAD-231366.

Predicting Brain Amyloid Status Using the National Institute of Health Toolbox (NIHTB) for Assessment of Neurological and Behavioral Function.

Cheng Y, Ho E, Weintraub S, Rentz D, Gershon R, Das S J Prev Alzheimers Dis. 2024; 11(4):943-957.

PMID: 39044505 PMC: 11269772. DOI: 10.14283/jpad.2024.77.

The impact of exercise on blood-based biomarkers of Alzheimer's disease in cognitively unimpaired older adults.

Sewell K, Rainey-Smith S, Pedrini S, Peiffer J, Sohrabi H, Taddei K Geroscience. 2024; 46(6):5911-5923.

PMID: 38488949 PMC: 11493998. DOI: 10.1007/s11357-024-01130-2.

Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors.

Kimura N, Aota T, Aso Y, Yabuuchi K, Sasaki K, Masuda T Alzheimers Res Ther. 2023; 15(1):212.

PMID: 38087316 PMC: 10714506. DOI: 10.1186/s13195-023-01363-x.

Body mass index, weight change in midlife, and dementia incidence: the Japan Public Health Center-based Prospective Study.

Tashiro M, Yasuda N, Inoue M, Yamagishi K, Tsugane S, Sawada N Alzheimers Dement (Amst). 2023; 15(4):e12507.

PMID: 38026757 PMC: 10668007. DOI: 10.1002/dad2.12507.

References

Donohue M, Sperling R, Salmon D, Rentz D, Raman R, Thomas R . The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014; 71(8):961-70. PMC: 4439182. DOI: 10.1001/jamaneurol.2014.803. View

Buchman A, Schneider J, Wilson R, Bienias J, Bennett D . Body mass index in older persons is associated with Alzheimer disease pathology. Neurology. 2006; 67(11):1949-54. DOI: 10.1212/01.wnl.0000247046.90574.0f. View

Growdon M, Schultz A, Dagley A, Amariglio R, Hedden T, Rentz D . Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015; 84(21):2153-60. PMC: 4451046. DOI: 10.1212/WNL.0000000000001614. View

Baumgartner R, Waters D, Gallagher D, Morley J, Garry P . Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999; 107(2):123-36. DOI: 10.1016/s0047-6374(98)00130-4. View

Dagley A, Lapoint M, Huijbers W, Hedden T, McLaren D, Chatwal J . Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2015; 144(Pt B):255-258. PMC: 4592689. DOI: 10.1016/j.neuroimage.2015.03.069. View

Tarnoki A, Tarnoki D, Bogl L, Medda E, Fagnani C, Nistico L . Association of body mass index with arterial stiffness and blood pressure components: a twin study. Atherosclerosis. 2013; 229(2):388-95. DOI: 10.1016/j.atherosclerosis.2013.05.001. View

Muller S, Preische O, Sohrabi H, Graber S, Jucker M, Dietzsch J . Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. Sci Rep. 2017; 7(1):1225. PMC: 5430642. DOI: 10.1038/s41598-017-01327-w. View

Papp K, Rentz D, Orlovsky I, Sperling R, Mormino E . Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y). 2017; 3(4):668-677. PMC: 5726754. DOI: 10.1016/j.trci.2017.10.004. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

10.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

11.

Morris J, Honea R, Vidoni E, Swerdlow R, Burns J . Is Alzheimer's disease a systemic disease?. Biochim Biophys Acta. 2014; 1842(9):1340-9. PMC: 4126236. DOI: 10.1016/j.bbadis.2014.04.012. View

12.

Blautzik J, Kotz S, Brendel M, Sauerbeck J, Vettermann F, Winter Y . Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment. J Alzheimers Dis. 2017; 65(3):781-791. DOI: 10.3233/JAD-170064. View

13.

Whitmer R, Sidney S, SELBY J, Johnston S, Yaffe K . Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005; 64(2):277-81. DOI: 10.1212/01.WNL.0000149519.47454.F2. View

14.

Rabin J, Klein H, Kirn D, Schultz A, Yang H, Hampton O . Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol. 2019; 76(10):1203-1210. PMC: 6635892. DOI: 10.1001/jamaneurol.2019.1879. View

15.

Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B . Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005; 62(10):1556-60. DOI: 10.1001/archneur.62.10.1556. View

16.

Landau S, Mintun M, Joshi A, Koeppe R, Petersen R, Aisen P . Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012; 72(4):578-86. PMC: 3786871. DOI: 10.1002/ana.23650. View

17.

Buchman A, Wilson R, Bienias J, Shah R, Evans D, Bennett D . Change in body mass index and risk of incident Alzheimer disease. Neurology. 2005; 65(6):892-7. DOI: 10.1212/01.wnl.0000176061.33817.90. View

18.

Donovan N, Locascio J, Marshall G, Gatchel J, Hanseeuw B, Rentz D . Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. Am J Psychiatry. 2018; 175(6):530-537. PMC: 5988933. DOI: 10.1176/appi.ajp.2017.17040442. View

19.

Hiller A, Ishii M . Disorders of Body Weight, Sleep and Circadian Rhythm as Manifestations of Hypothalamic Dysfunction in Alzheimer's Disease. Front Cell Neurosci. 2018; 12:471. PMC: 6289975. DOI: 10.3389/fncel.2018.00471. View

20.

Hanseeuw B, Jonas V, Jackson J, Betensky R, Rentz D, Johnson K . Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry. 2018; 25(10):2599-2607. PMC: 6377864. DOI: 10.1038/s41380-018-0214-2. View